TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

TCL.AU

13.52

-0.52%↓

BXB.AU

20.37

-1.07%↓

COL.AU

20.26

+2.22%↑

QAN.AU

8.59

-2.61%↓

CAR.AU

32.73

-1.24%↓

Search

CSL Ltd

Cerrado

SectorAcciones industriales

257.01 0.65

Resumen

Variación precio

24h

Actual

Mínimo

250.43

Máximo

257.24

Métricas clave

By Trading Economics

Ingresos

1.3B

2B

Ventas

1.5B

8.2B

P/B

Media del Sector

28.972

33.198

BPA

1.831

Rentabilidad por dividendo

1.7

Margen de beneficio

24.437

Empleados

32,698

EBITDA

1.5B

3.2B

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+26.05% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

1.70%

2.54%

Fecha Próximo Dividendo

9 abr 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-14B

121B

Apertura anterior

256.36

Cierre anterior

257.01

Noticias sobre sentimiento de mercado

By Acuity

34%

66%

121 / 468 Clasificación en Industrials

CSL Ltd Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

10 feb 2025, 21:55 UTC

Ganancias

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:34 UTC

Ganancias

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

12 ago 2024, 23:23 UTC

Ganancias

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12 ago 2024, 22:49 UTC

Ganancias

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

21 mar 2025, 02:03 UTC

Charlas de Mercado

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

11 feb 2025, 22:30 UTC

Charlas de Mercado

Flu Vaccines Proving Problematic for CSL -- Market Talk

10 feb 2025, 21:40 UTC

Ganancias

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

10 feb 2025, 21:19 UTC

Ganancias

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

10 feb 2025, 21:13 UTC

Ganancias

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

10 feb 2025, 21:12 UTC

Ganancias

CSL Interim Dividend US$1.30/Security

10 feb 2025, 21:12 UTC

Ganancias

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

10 feb 2025, 21:11 UTC

Ganancias

CSL 1H Net Profit US$2.07 Billion, Up 3% on Year

7 nov 2024, 03:53 UTC

Charlas de Mercado

U.S. Tariffs Could Force Moves by Australian Med-Techs -- Market Talk

22 oct 2024, 22:53 UTC

Charlas de Mercado

CSL's R&D Update Seen as Neutral Overall -- Market Talk

10 oct 2024, 22:20 UTC

Charlas de Mercado

CSL Bull Looking for Update on Gross Margin -- Market Talk

13 ago 2024, 00:33 UTC

Charlas de Mercado

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12 ago 2024, 22:34 UTC

Ganancias

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12 ago 2024, 22:18 UTC

Ganancias

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12 ago 2024, 22:18 UTC

Ganancias

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12 ago 2024, 22:17 UTC

Ganancias

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12 ago 2024, 22:16 UTC

Ganancias

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12 ago 2024, 22:15 UTC

Ganancias

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12 ago 2024, 22:14 UTC

Ganancias

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12 ago 2024, 22:13 UTC

Ganancias

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12 ago 2024, 22:13 UTC

Ganancias

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12 ago 2024, 22:11 UTC

Ganancias

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12 ago 2024, 22:10 UTC

Ganancias

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12 ago 2024, 22:09 UTC

Ganancias

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12 ago 2024, 22:08 UTC

Ganancias

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12 ago 2024, 22:07 UTC

Ganancias

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

Comparación entre iguales

Cambio de precio

CSL Ltd Esperado

Precio Objetivo

By TipRanks

26.05% repunte

Estimación a 12 meses

Media 317.092 AUD  26.05%

Máximo 360.3 AUD

Mínimo 250 AUD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CSL Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

12

Comprar

2

Mantener

0

Vender

Sentimiento

By Acuity

121 / 468 Clasificación en Acciones industriales

Noticias sobre sentimiento de mercado

Coyuntura alcista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.